NCT05687682View on ClinicalTrials.gov

Safety of AM-928 Infusion in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

AM-928

AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.

Trial Locations (1)

10002

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

AcadeMab Biomedical Inc.

INDUSTRY